A growing arsenal of non-insulin diabetes medications is expanding therapeutic options beyond traditional insulin therapy. GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated significant benefits in glycemic control while reducing cardiovascular risks. DPP-4 inhibitors offer a convenient oral alternative, particularly for patients seeking weight-neutral treatments. Recent advancements include combination therapies that target multiple metabolic pathways simultaneously, enhancing efficacy while minimizing side effects. Additionally, bile acid sequestrants, dopamine agonists, and amylin analogs provide novel mechanisms for improving insulin sensitivity. With continued research into incretin-based therapies and dual-agonist formulations, non-insulin medications are playing a crucial role in personalized diabetes management.
Yong Xiao Wang
Albany Medical College, United States
F Buck Willis
Christian College of Medicine, Belize
Amy Gutman
AdventHealth; Tough Love MD, United States
Sujith Rajan
NYU Long Island School of Medicine, United States
Anil Harrison
Midwestern University, United States
Jun Dai
Des Moines University, United States
David Petch
utR Biotech, CanadaSubmit your abstract Today
Title : Does winter melon (Benincasa hispida) improves nutritional values and ameliorating glycaemic parameters
Wan Rosli Wan Ishak, Universiti Sains Malaysia, Malaysia
Title : The menopausal mind: Reframing female senescence as a neuroendocrine disorder with root cause management strategies
Amy Gutman, AdventHealth; Tough Love MD, United States
Title : Diabetes reduction (pre diabetes and type 2) with integrative medicine
F Buck Willis, Christian College of Medicine, Belize
Title : Adipose MTP deficiency protects against hepatic steatosis by upregulating PPAR activity
Sujith Rajan, NYU Long Island School of Medicine, United States
Title : AI receptor binding studies reveal GPR146 conformational states across diabetic phenotypes: Analysis of C peptide and insulin interactions in cholesterol metabolism cortisol regulation and the vitamin D renin angiotensin axis
David Petch, utR Biotech, Canada
Title : Comparative outcomes of antihypertensive therapy in black vs non hispanic white patients with hypertension and cardiovascular disease
Anil Harrison, Midwestern University, United States